Adjustments related to prior year sales Gross To Net Adjustments Reserve Provision Related To Prior Period Sales Gross To Net Adjustments Reserve Provision Related To Prior Period Sales Revision of Prior Period [Axis] Revision of Prior Period [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Restricted cash Restricted Cash, Current Award Timing Predetermined Award Timing Predetermined [Flag] Entity File Number Entity File Number Additional paid-in Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Customer B Customer B [Member] Customer B Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Number of core values supporting Segment Reporting, Number Of Core Values Supporting Operating Decisions Segment Reporting, Number Of Core Values Supporting Operating Decisions Number of office lease amendment Operating Lease, Number Of Amendments Operating Lease, Number Of Amendments Unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic net loss per common, Series A preferred, and Series B preferred share (in dollars per share) Basic net loss per common, Series A preferred, and Series B preferred share (in dollars per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common stock, capital shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Product Revenue, Net Revenue from Contract with Customer [Text Block] Accounts payable Increase (Decrease) in Accounts Payable, Trade Variable Rate Component One Variable Rate Component One [Member] Variable Rate Component One Schedule of Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Inventory Disclosure [Abstract] Schedule of Cash, Cash Equivalents and Available-for-Sale Marketable Securities Cash, Cash Equivalent, and Investment [Table Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Concentration risk, percentage (as a percent) Concentration Risk, Percentage Principle of Consolidation Consolidation, Policy [Policy Text Block] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Stock options Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Preferred stock conversion ratio (in shares) Preferred Stock, Convertible, Conversion Ratio Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Insider Trading Policies and Procedures [Line Items] Stock-based compensation Stock-based compensation Share-Based Payment Arrangement, Expense Common stock, shares authorized (in shares) Common Stock, Shares Authorized Reportable Segment Reportable Segment [Member] Reportable Segment Number of additional early stage MASH assets Number of Additional Early Stage MASH Assets Number of Additional Early Stage MASH Assets Issuance of common stock under equity plans (in shares) Stock Issued During Period, Shares, New Issues Current assets: Assets, Current [Abstract] Options cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Total liabilities and stockholders’ equity Liabilities and Equity Anti-dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Line of credit facility, interest rate (as a percent) Line of Credit Facility, Interest Rate at Period End Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Cover [Abstract] Cover [Abstract] Total cash, cash equivalents and restricted cash Cash and Cash Equivalents, Fair Value Disclosure Facility related and other internal expenses Facility And Other Expenses Facility And Other Expenses Maximum Maximum [Member] Exercisable at the ending of the year (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Suzhou Ribo Life Science Co. Ltd. And Ribocure Pharmaceuticals AB Suzhou Ribo Life Science Co. Ltd. And Ribocure Pharmaceuticals AB [Member] Suzhou Ribo Life Science Co. Ltd. And Ribocure Pharmaceuticals AB Accounting Policies [Abstract] Accounting Policies [Abstract] Intangible assets, net Finite-Lived Intangible Assets, Net Concentration Risk Type [Domain] Concentration Risk Type [Domain] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Debt Instrument [Line Items] Commitments and Contingencies Debt Instrument [Line Items] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Share-based payment award, equity instruments other than options, vested in period, fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Operating lease, liability Operating Lease, Liability Series B preferred stock Series B Preferred Stock [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Amortization and interest accretion related to operating leases Operating Lease, Right-Of-Use Asset, Periodic Reduction (Increase) Operating Lease, Right-Of-Use Asset, Periodic Reduction (Increase) Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Entity Shell Company Entity Shell Company Rebates, returns and other revenue related reserves Rebates, Returns And Other Revenue Related Reserves, Current Rebates, Returns And Other Revenue Related Reserves, Current Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Eligible to Earn PSUs Eligible to Earn Performance Share [Member] Eligible to Earn Performance Share The Financing Agreement The Financing Agreement [Member] The Financing Agreement Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Operating lease prepayment amount Prepaid Operating Lease Prepaid Operating Lease Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Name Measure Name Secured Debt Secured Debt [Member] Operating lease liabilities Operating Lease, Liability, Current Document Fiscal Period Focus Document Fiscal Period Focus Corporate debt securities with original maturities of 1 to 2 years (Level 2) Corporate Debt Securities Due Within One To Two Years Of Date Of Purchase [Member] Corporate Debt Securities Due Within One To Two Years Of Date Of Purchase Award Timing Method Award Timing Method [Text Block] Common stock, capital additional shares reserved for future issuance (in shares) Common Stock, Additional Capital Shares Reserved For Future Issuance Common Stock, Additional Capital Shares Reserved For Future Issuance Award Type [Axis] Award Type [Axis] Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward] Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward] Loan payable, net of discount Long-Term Debt Total assets Assets Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Stockholders' Equity (Deficit) Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Trading Symbol Trading Symbol RSUs vested (in dollars per share) PSUs attained (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Debt instrument, interest rate, penalty (as a percent) Debt Instrument, Prepayment Penalty, Percentage Debt Instrument, Prepayment Penalty, Percentage Geographical [Domain] Geographical [Domain] Income Taxes Income Tax, Policy [Policy Text Block] Entity Address, City or Town Entity Address, City or Town Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Other segment (expense) income Segment Reporting, Other Segment Item, Amount Foreign currency translation gain Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Concentration Risk Type [Axis] Concentration Risk Type [Axis] Inventory Inventory Disclosure [Text Block] Richard Levy, M.D [Member] Richard Levy, M.D Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Restricted stock units Restricted Stock Units (RSUs) Restricted stock units Restricted Stock Units (RSUs) [Member] Number of votes per share that common stockholders are entitled to receive Common Stock Voting Rights Number Represents the number of votes per share that common stockholders are entitled to receive. Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Clinical study, manufacturing and drug supply Accrued Clinical Study, Manufacturing and Drug Supply, Current Accrued manufacturing and drug supply Current. Entity Emerging Growth Company Entity Emerging Growth Company 2029 Long-Term Debt, Maturity, Year Three Research and development Research and Development Expense (Excluding Acquired in Process Cost) Warrants Warrant [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Obtaining an operating lease right-of-use asset in exchange for an operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Outstanding at the beginning of the year (in shares) Outstanding at the ending of the year (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Accounts receivable writeoff Accounts Receivable, Credit Loss Expense (Reversal) Plan Name [Axis] Plan Name [Axis] PEO PEO [Member] Interest income Investment Income, Interest Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Intangible Assets, Net Intangible Assets, Finite-Lived, Policy [Policy Text Block] Accumulated deficit Retained Earnings [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Preferred stock price, hurdles period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Preferred Stock Price, Period To Achieve Hurdle Share-Based Compensation Arrangement by Share-Based Payment Award, Preferred Stock Price, Period To Achieve Hurdle Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Incremental common shares attributable to dilutive effect of conversion of preferred stock Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Sale of Stock [Domain] Sale of Stock [Domain] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Product and Service [Domain] Product and Service [Domain] Marketable securities: Debt Securities, Available-for-Sale [Abstract] Customer Concentration Risk Customer Concentration Risk [Member] Customer E Customer E [Member] Customer E Schedule of Performance-Based Restricted Stock Units Activity Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Revenue Benchmark Revenue from Contract with Customer, Product and Service Benchmark [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Schedule of Error Corrections and Prior Period Adjustments Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] City Area Code City Area Code Collaborative arrangement, milestone payment, eligible to receive Collaborative Arrangement, Milestone Payment, Eligible to Receive Collaborative Arrangement, Milestone Payment, Eligible to Receive Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Aggregate principal amount not to exceed Line of Credit Facility, Accordion Feature, Increase Limit Line of Credit Facility, Accordion Feature, Increase Limit Pre-funded warrants Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Subsequent Event Subsequent Event [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Cost of sales Cost of Sales [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Money market funds Money Market Funds [Member] Equity Components [Axis] Equity Components [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk [Table] Concentration Risk [Table] Hoffmann-La Roche ("Roche") Hoffman La Roche [Member] Represents information pertaining to Hoffman-La Roche. Number of reportable segments Number of Reportable Segments Customer D Customer D [Member] Customer D West Conshohocken, Pennsylvania West Conshohocken, Pennsylvania [Member] West Conshohocken, Pennsylvania Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cost Debt Securities, Available-for-Sale, Amortized Cost Other Performance Measure, Amount Other Performance Measure, Amount Weighted average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] U.S. Government and Government Sponsored Entities US Treasury and Government [Member] Entity Address, State or Province Entity Address, State or Province Delayed Draw Term Loan Delayed Draw Term Loan (DDTL) [Member] Marketable Securities Marketable Securities, Policy [Policy Text Block] Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total current liabilities Liabilities, Current Individual: Individual [Axis] Vesting [Axis] Vesting [Axis] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Research and development Research and Development Expense [Member] Additional paid-in-capital Additional Paid in Capital, Common Stock Provision related to sales in the current year Gross To Net Adjustments Reserve Provision Related To Current Period Sales Gross To Net Adjustments Reserve Provision Related To Current Period Sales Net cash provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Document Fiscal Year Focus Document Fiscal Year Focus Liquidity and Uncertainties Substantial Doubt about Going Concern [Text Block] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Repayments of long-term debt Repayments of Long-Term Debt Entity Interactive Data Current Entity Interactive Data Current Plan Name [Domain] Plan Name [Domain] Weighted average remaining period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Cost Cash, Cash Equivalents, Restricted Cash and Short-term Investments, At Cost This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings, and cash and cash equivalents. Equity [Abstract] Revenue Recognition and Product Revenue, Net Revenue from Contract with Customer [Policy Text Block] Purchase obligation Purchase Obligation Segment Information Segment Reporting Disclosure [Text Block] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Valuation allowance on deferred tax assets (as a percent) Deferred Tax Assets, Percentage Of Valuation Allowance The percentage of valuation allowance on the deferred tax assets. Convertible Series A and B Preferred Stock Convertible Series A and B Preferred Stock [Member] Convertible Series A and B Preferred Stock [Member] Convertible Series A and B Preferred Stock [Member] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Leases Lessee, Leases [Policy Text Block] Research, Development and Commercialization Agreement Research Development And Commercialization Agreement [Member] Represents information pertaining to Research, Development and Commercialization Agreement with Hoffmann-La Roche ("Roche") which grants a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement. Selling, general and administrative Selling, General and Administrative Expense Depreciation and amortization expense Depreciation, Depletion and Amortization Other noncurrent assets Other Assets, Noncurrent Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Schedule of Maturities of Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Trade Receivables, Net Accounts Receivable [Policy Text Block] Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Share-Based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Milestone payment due Collaborative Arrangement, Contingent Consideration, Liability, Milestone Payment Collaborative Arrangement, Contingent Consideration, Liability, Milestone Payment Customer C Customer C [Member] Customer C Segments [Axis] Segments [Axis] Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Work in process Inventory, Work in Process, Net of Reserves Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category 2024 Pre-Funded Warrants 2024 Pre-Funded Warrants [Member] 2024 Pre-Funded Warrants Class of Stock [Domain] Class of Stock [Domain] Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Share price (in dollars per share) Share Price Subsequent Event Type [Axis] Subsequent Event Type [Axis] Stock-based Compensation Share-Based Payment Arrangement [Text Block] Assets Assets [Abstract] Loan payable, net of discount Long-Term Debt, Excluding Current Maturities Credit Facility [Axis] Credit Facility [Axis] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Share-based compensation arrangement by share-based payment award, equity instruments other than options, earned in hurdle two (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Earned in Hurdle Two Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Earned in Hurdle Two Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Entity Address, Address Line Three Entity Address, Address Line Three Vesting [Domain] Vesting [Domain] Debt Instrument [Axis] Debt Instrument [Axis] RSUs forfeited (in dollars per share) PSUs forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Credit Facility [Domain] Credit Facility [Domain] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Customer A Customer A [Member] Customer A Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Chargebacks, Discounts for Prompt Pay and Other Allowances Chargebacks, Discounts for Prompt Pay and Other Allowances [Member] Chargebacks, Discounts for Prompt Pay and Other Allowances Fair Value as of Grant Date Award Grant Date Fair Value Entity Registrant Name Entity Registrant Name Share-based compensation arrangement by share-based payment award, equity instruments other than options, earned in hurdle one (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Earned in Hurdle One Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Earned in Hurdle One Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Compensation and benefit-related expenses Labor and Related Expense Weighted average earned PSUs Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements RSUs granted (in shares) PSUs granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period RSUs forfeited (in shares) PSUs forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unrecognized stock compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Beneficial ownership notice period (in days) Class Of Warrant Or Right, Beneficial Ownership, Exercise Percentage Notice Period Class Of Warrant Or Right, Beneficial Ownership, Exercise Percentage Notice Period Document Quarterly Report Document Quarterly Report Revision of Prior Period [Domain] Revision of Prior Period [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Number of operating segments Number of Operating Segments 2023 Inducement Plan Inducement Plan 2023 [Member] Two Thousand And Twenty Three Stock Inducement Plan [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] RSUs granted (in dollars per share) PSUs granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Non-PEO NEO Non-PEO NEO [Member] Variable Rate Component Two Variable Rate Component Two [Member] Variable Rate Component Two Lessee, operating lease, lease not yet commenced, term of contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Sale of Stock [Axis] Sale of Stock [Axis] Unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Name Trading Arrangement, Individual Name As Reported Previously Reported [Member] Equity Award [Domain] Award Type [Domain] Equity Awards Adjustments Equity Awards Adjustments [Member] Other non-cash items, net Other Noncash Income (Expense) Selling, general and administrative Accrued Selling, General and Administrative, Current Accrued Selling, General and Administrative, Current Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Compensation Amount Outstanding Recovery Compensation Amount Debt instrument, face amount Debt Instrument, Face Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Cost of sales Operating Costs and Expenses Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Preferred stock Preferred Stock [Member] Schedule of Investments [Line Items] Schedule of Investments [Line Items] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Unvested, beginning balance (in dollars per share) Unvested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Revenues: Revenues [Abstract] 2015 Stock Plan Stock Plan 2015 [Member] Two thousand and fifteen stock plan Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax 2027 Long-Term Debt, Maturity, Year One Incremental common shares excluded from the dilutive effect (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Incremental Common Shares Subject To Delayed Settlement Share-Based Compensation Arrangement by Share-Based Payment Award, Incremental Common Shares Subject To Delayed Settlement Major Types of Debt and Equity Securities [Domain] Financial Instruments [Domain] Net unrealized loss on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax David Soergel, M.D [Member] David Soergel, M.D Segments [Domain] Segments [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Stock options, restricted stock and performance stock units convertible, shares issuable (in shares) Common Stock, Capital Shares Granted And Issuable Common Stock, Capital Shares Granted And Issuable Unearned performance-based restricted stock units Performance-Based Restricted Stock Units (PSUs) Performance-based restricted stock units Performance Shares [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Maximum of eligible milestone payments Research And Development, Maximum Aggregate Milestone Payments Research And Development, Maximum Aggregate Milestone Payments Inventory Increase (Decrease) in Inventories Inventory Total inventory Inventory, Net Amortization of debt issuance costs and discount Amortization of Debt Issuance Costs and Discounts Number of warrants issued for purchase of common shares (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Debt instrument, interest rate during period Debt Instrument, Basis Spread On Variable Rate, Floor Debt Instrument, Basis Spread On Variable Rate, Floor Company Selected Measure Name Company Selected Measure Name Cost of Sales Cost of Goods and Service [Policy Text Block] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Long Term Debt Debt Disclosure [Text Block] Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at March 31, 2026 and December 31, 2025; 2,369,797 shares issued and outstanding at March 31, 2026 and December 31, 2025 Preferred Stock, Value, Issued Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Less amount representing interest Interest Payable Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Number of siRNA candidates Number of siRNA Candidates Number of siRNA Candidates Finished goods Inventory, Finished Goods, Net of Reserves Common stock, par value $0.0001 per share authorized: 200,000,000 shares at March 31, 2026 and December 31, 2025; 23,041,918 and 22,842,073 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively Common Stock, Value, Issued Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Share-Based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Diluted weighted average number of shares outstanding (Note 13) (in shares) Weighted Average Number of Shares Outstanding, Diluted Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Small Business Entity Small Business Preferred stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Preferred Stock, Shares Outstanding Number of stock price appreciation hurdles achieved Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Stock Price Appreciation Hurdles Achieved Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Stock Price Appreciation Hurdles Achieved Patents Patents [Policy Text Block] Disclosure of accounting policy for patents. Document Transition Report Document Transition Report Repayments of long-term lines of credit, gross Repayments Of Long-Term Lines Of Credit, Gross Repayments Of Long-Term Lines Of Credit, Gross Schedule of Concentrations of Credit Risk and Significant Customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Underlying Securities Award Underlying Securities Amount Concentration Risk [Line Items] Concentration Risk [Line Items] Equity Component [Domain] Equity Component [Domain] Provision for excess inventory Provision For Excess Inventory Provision For Excess Inventory Document Period End Date Document Period End Date PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Cash, Cash Equivalents, Restricted Cash and Marketable Securities Cash, Cash Equivalent, and Marketable Security [Text Block] Allowance for credit loss Accounts Receivable, Allowance for Credit Loss Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Revenue from Contract with Customer [Abstract] Schedule of Investments [Table] Schedule of Investments [Table] Fair value Cash, Cash Equivalents, Restricted Cash, And Short-Term Investments Cash, Cash Equivalents, Restricted Cash, And Short-Term Investments Loan Facility Loan Facility [Member] Loan facility member. Document Type Document Type Net Loss per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Product and Service [Axis] Product and Service [Axis] Product revenue, net Revenue from Contract with Customer, Excluding Assessed Tax All Individuals All Individuals [Member] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Purchases of property and equipment, net of disposals Payments to Acquire Property, Plant, and Equipment Name Forgone Recovery, Individual Name Expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Pfizer Pfizer [Member] Pfizer Authorized capital Share Repurchase Program, Authorized, Amount Weighted average common shares outstanding Weighted Average Number of Shares Issued, Basic Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Total intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Schedule of Gross to Net Adjustments Reserve Schedule Of Gross To Net Adjustments Reserve [Table Text Block] Schedule Of Gross To Net Adjustments Reserve Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] U.S. government and GSE securities with original maturities of 1 year or less (Level 2) US Treasury And Government Due Within One Year [Member] US Treasury And Government Due Within One Year Accrued Liabilities, Current [Abstract] Accrued Liabilities, Current [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Total other comprehensive gain (loss): Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Current liabilities: Liabilities, Current [Abstract] Geographical [Axis] Geographical [Axis] Payments and customer credits issued Gross To Net Adjustments Reserve Credits And Payments Made Gross To Net Adjustments Reserve Credits And Payments Made Total operating expenses Operating Expenses Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Accrued liabilities Increase (Decrease) in Accrued Liabilities Diluted net loss per common, Series A preferred, and Series B preferred share (in dollars per share) Diluted net loss per common, Series A preferred, and Series B preferred share (in dollars per share) Earnings Per Share, Diluted Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Trade receivables, net Accounts Receivable, after Allowance for Credit Loss, Current Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Title of 12(b) Security Title of 12(b) Security Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Stock-based compensation expense related to equity-classified awards APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Net loss per common, Series A preferred and Series B preferred share: Earnings Per Share [Abstract] Term charges on aggregate principal amount, (as a percent) Debt Instrument, End Of Term Charge Debt Instrument, End Of Term Charge Faroe License Faroe License [Member] Faroe License Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Marketable securities Debt Securities, Available-for-Sale, Current Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Upfront payment Research And Development, Upfront Payment Research And Development, Upfront Payment 2023 Pre-Funded Warrants 2023 Pre-Funded Warrants [Member] 2023 Pre-Funded Warrants Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Award Timing Disclosures [Line Items] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Long-term debt Long-Term Debt, Gross Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Variable Rate [Axis] Variable Rate Component [Axis] Variable Rate Component Compensation and benefits Employee-related Liabilities, Current Stockholders' Equity Equity [Text Block] Net loss Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Expiration Date Trading Arrangement Expiration Date Long term liabilities: Liabilities, Noncurrent [Abstract] 2025 Inducement Plan Inducement Plan 2025 [Member] Inducement Plan 2025 Other Other Accrued Liabilities, Current Remainder of future milestone payments Remaining Milestone Payments The amount of future milestone payments remaining to be paid under the agreement. Share-based compensation arrangement by share-based payment award, award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Property and equipment, net Property, Plant and Equipment, Net Arrowhead License Arrowhead License [Member] Arrowhead License Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Adoption Date Trading Arrangement Adoption Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Trade receivables, net Increase (Decrease) in Accounts Receivable Inventory Inventory, Policy [Policy Text Block] Series A preferred stock Series A Preferred Stock [Member] Entity Current Reporting Status Entity Current Reporting Status Lessee, operating lease, term of contract (in days) Lessee, Operating Lease, Term of Contract Customer [Axis] Customer [Axis] Selling, General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Rebates, Co-Pay Assistance, Returns, and Other Rebates, Co-Pay Assistance, Returns, and Other [Member] Rebates, Co-Pay Assistance, Returns, and Other Loss from operations Operating Income (Loss) Line of Credit Line of Credit [Member] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Share-based compensation arrangement by share-based payment award, equity instruments other than options, eligible to be earned in hurdle three (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Eligible To Be Earned in Hurdle Three Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Eligible To Be Earned in Hurdle Three Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Class of Stock [Axis] Class of Stock [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Balance, beginning Balance, ending Gross To Net Adjustments Reserve Gross To Net Adjustments Reserve Subsequent Event Type [Domain] Subsequent Event Type [Domain] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Professional fees and other external expenses Professional Fees Number of research and development categories Segment Reporting, Number Of Research And Development Categories Segment Reporting, Number Of Research And Development Categories Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Shares available for future issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Statement [Table] Statement [Table] Other expense, net Other Nonoperating Income (Expense) U.S. government and GSE securities with original maturities of 1 to 2 years (Level 2) US Treasury And Government Due Within One To Two Years [Member] US Treasury And Government Due Within One To Two Years Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash Cash [Member] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Number of stock price appreciation hurdles Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Stock Price Appreciation Hurdles Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Stock Price Appreciation Hurdles Organization, Business, and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unrecorded unconditional purchase obligation, including lease not yet commenced, total Unrecorded Unconditional Purchase Obligation All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag CSPC CSPC Pharmaceutical Group Limited [Member] CSPC Pharmaceutical Group Limited 2028 Long-Term Debt, Maturity, Year Two Termination Date Trading Arrangement Termination Date Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accrued interest, net of interest received on maturity of investments Increase (Decrease) In Accrued Interest, Net Of Interest Received The increase (decrease) during the reporting period in the aggregate amount of accrued interest expense incurred but not yet paid, net of interest received on maturity of investments. Measure: Measure [Axis] Raw materials Inventory, Raw Materials, Net of Reserves Schedule of Stock Option Activity and Stock-Based Compensation Expense Share-Based Payment Arrangement, Option, Activity [Table Text Block] Basic weighted average number of shares outstanding (Note 13) (in shares) Basic weighted average number of shares outstanding (Note 13) (in shares) Weighted Average Number of Shares Outstanding, Basic Cost of sales Cost of Product and Service Sold Warrants and rights outstanding Warrants and Rights Outstanding Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Exercisable at the ending of the year (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Entity Tax Identification Number Entity Tax Identification Number Pre-Funded Warrants Pre-Funded Warrants [Member] Pre FundedWarrants [Member] Operating expenses: Costs and Expenses [Abstract] Less unamortized discount Debt Instrument, Unamortized Discount Outstanding at the beginning of the year (in dollars per share) Outstanding at the ending of the year (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Minimum unrestricted cash balance Debt Instrument, Covenant, Unrestricted Cash, Minimum Debt Instrument, Covenant, Unrestricted Cash, Minimum Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Unrecognized stock-based compensation expense Stock-based compensation expense Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued 2030 Long-Term Debt, Maturity, Year Four Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Use of Estimates Use of Estimates, Policy [Policy Text Block] Number of selling, general and administrative categories Segment Reporting, Number Of Selling, General And Administrative Categories Segment Reporting, Number Of Selling, General And Administrative Categories Interest expense Interest expense Interest Expense, Nonoperating Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Options cancelled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Variable Rate [Domain] Variable Rate Component [Domain] Variable Rate Component [Domain] 2026 Long-Term Debt, Maturity, Remainder of Fiscal Year Total long term liabilities Liabilities, Noncurrent Total liabilities Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Purchases of property and equipment in accounts payable Capital Expenditures Incurred but Not yet Paid Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Sales and maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Preferred shares number voting rights Preferred Stock, Number Of Voting Rights Number of voting rights of preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. 2024 Sales Agreement 2024 Sales Agreement [Member] 2024 Sales Agreement Issuance of common stock under equity plans Stock Issued During Period, Value, New Issues Statement Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Counterparty Name [Axis] Counterparty Name [Axis] Common stock Common Stock [Member] RSUs vested (in shares) PSUs attained (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Fair value Debt Securities, Available-for-Sale Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Corporate Debt Securities Corporate Debt Securities [Member] Net increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Product [Member]